Status:
UNKNOWN
Tryptophan Metabolites in Pediatric Migraine
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Migraine in Children
Eligibility:
All Genders
4-18 years
Brief Summary
Background: Migraine is a common neurological disorder that also has a significant prevalence in children. Although the exact etiology of migraine is unknown, recent studies suggest an association be...
Detailed Description
Method for determination of tryptophan metabolite content: 1. Timing of blood collection In the case group, blood was collected at any time during the first 2-4 hours of the migraine attack; in the i...
Eligibility Criteria
Inclusion
- Age 4-18 years, male or female.
- Meet the ICHD-3 diagnostic criteria for migraine with aura, without aura, and chronic migraine.
- Migraine is diagnosed by two or more specialized neurologists.
- PedMIDAS score was more than 11.
- Migraine was never treated.
- Patients and family members gave informed consent to the study's purpose, significance, risks, benefits, and information of the study.
Exclusion
- Presence of drug overdose.
- Autoimmune diseases.
- Neurological disorders other than migraine, intracranial masses.
- Congenital or genetic disorders.
- Diabetes, bronchial asthma, cardiovascular disease, pulmonary disease.
- Other types of primary and secondary headaches.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05969990
Start Date
January 1 2022
End Date
December 31 2023
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Junhui Liu
Jinan, China, 250012